45 related articles for article (PubMed ID: 31528688)
1. Integrative analysis of multi-omics data reveals inhibition of RB1 signaling promotes apatinib resistance of hepatocellular carcinoma.
He K; An S; Liu F; Chen Y; Xiang G; Wang H
Int J Biol Sci; 2023; 19(14):4511-4524. PubMed ID: 37781033
[TBL] [Abstract][Full Text] [Related]
2. Selective Inhibition of Aurora Kinase A by AK-01/LY3295668 Attenuates MCC Tumor Growth by Inducing MCC Cell Cycle Arrest and Apoptosis.
Das BK; Kannan A; Nguyen Q; Gogoi J; Zhao H; Gao L
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359608
[TBL] [Abstract][Full Text] [Related]
3. Targeting the evolution of drug resistance in lung cancer.
Shah KN; Bandyopadhyay S
Mol Cell Oncol; 2019; 6(5):e1603092. PubMed ID: 31528688
[TBL] [Abstract][Full Text] [Related]
4. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
5. Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Phan AN; Hua TN; Kim MK; Vo VT; Choi JW; Kim HW; Rho JK; Kim KW; Jeong Y
Oncotarget; 2016 Aug; 7(34):54702-54713. PubMed ID: 27419630
[TBL] [Abstract][Full Text] [Related]
6. Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer.
Jacobsen K; Bertran-Alamillo J; Molina MA; Teixidó C; Karachaliou N; Pedersen MH; Castellví J; Garzón M; Codony-Servat C; Codony-Servat J; Giménez-Capitán A; Drozdowskyj A; Viteri S; Larsen MR; Lassen U; Felip E; Bivona TG; Ditzel HJ; Rosell R
Nat Commun; 2017 Sep; 8(1):410. PubMed ID: 28871105
[TBL] [Abstract][Full Text] [Related]
7. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
8. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
[TBL] [Abstract][Full Text] [Related]
9. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.
Shah KN; Bhatt R; Rotow J; Rohrberg J; Olivas V; Wang VE; Hemmati G; Martins MM; Maynard A; Kuhn J; Galeas J; Donnella HJ; Kaushik S; Ku A; Dumont S; Krings G; Haringsma HJ; Robillard L; Simmons AD; Harding TC; McCormick F; Goga A; Blakely CM; Bivona TG; Bandyopadhyay S
Nat Med; 2019 Jan; 25(1):111-118. PubMed ID: 30478424
[TBL] [Abstract][Full Text] [Related]
10. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.
Blakely CM; Watkins TBK; Wu W; Gini B; Chabon JJ; McCoach CE; McGranahan N; Wilson GA; Birkbak NJ; Olivas VR; Rotow J; Maynard A; Wang V; Gubens MA; Banks KC; Lanman RB; Caulin AF; St John J; Cordero AR; Giannikopoulos P; Simmons AD; Mack PC; Gandara DR; Husain H; Doebele RC; Riess JW; Diehn M; Swanton C; Bivona TG
Nat Genet; 2017 Dec; 49(12):1693-1704. PubMed ID: 29106415
[TBL] [Abstract][Full Text] [Related]
11. Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy.
McCoach CE; Blumenthal GM; Zhang L; Myers A; Tang S; Sridhara R; Keegan P; Pazdur R; Doebele RC; Kazandjian D
Ann Oncol; 2017 Nov; 28(11):2707-2714. PubMed ID: 29045514
[TBL] [Abstract][Full Text] [Related]
12. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
Mok TS; Wu Y-L; Ahn M-J; Garassino MC; Kim HR; Ramalingam SS; Shepherd FA; He Y; Akamatsu H; Theelen WS; Lee CK; Sebastian M; Templeton A; Mann H; Marotti M; Ghiorghiu S; Papadimitrakopoulou VA;
N Engl J Med; 2017 Feb; 376(7):629-640. PubMed ID: 27959700
[TBL] [Abstract][Full Text] [Related]
13. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.
Hata AN; Niederst MJ; Archibald HL; Gomez-Caraballo M; Siddiqui FM; Mulvey HE; Maruvka YE; Ji F; Bhang HE; Krishnamurthy Radhakrishna V; Siravegna G; Hu H; Raoof S; Lockerman E; Kalsy A; Lee D; Keating CL; Ruddy DA; Damon LJ; Crystal AS; Costa C; Piotrowska Z; Bardelli A; Iafrate AJ; Sadreyev RI; Stegmeier F; Getz G; Sequist LV; Faber AC; Engelman JA
Nat Med; 2016 Mar; 22(3):262-9. PubMed ID: 26828195
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
